Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ANGLE plc ( (GB:CLBX) ) has issued an announcement.
CelLBxHealth has used the first quarter of 2026 to push through a deep organisational restructuring under its revised strategy, cutting headcount to 39 and delivering more than £6.6 million in annualised cash operating cost savings, with further reductions planned in the second quarter. Cash stood at £4.3 million at the end of March, reflecting restructuring costs, as management seeks to right-size the business while maintaining capability to meet commercial milestones.
Alongside cost-cutting, the company is sharpening its commercial push, appointing a new U.S. head of sales and targeting at least £2.1 million in revenue for 2026, a 50% increase on the prior year. CelLBxHealth is in advanced talks with a major private U.S. healthcare provider on two clinical studies and close to a master services deal with a top ten global pharma group to use its Parsortix platform, signalling potential step-change contracts that could further lift revenue guidance and strengthen its position in oncology diagnostics and drug development.
The most recent analyst rating on (GB:CLBX) stock is a Buy with a £30.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:CLBX Stock Forecast page.
Spark’s Take on CLBX Stock
According to Spark, TipRanks’ AI Analyst, CLBX is a Neutral.
The overall stock score reflects significant financial challenges and bearish technical indicators, which are the most impactful factors. While recent corporate events and earnings call achievements provide some positive outlook, the financial and valuation concerns weigh heavily on the score.
To see Spark’s full report on CLBX stock, click here.
More about ANGLE plc
CelLBxHealth plc is a CTC intelligence company developing innovative circulating tumor cell solutions for research, drug development and clinical oncology. Its patent-protected Parsortix platform isolates CTCs from blood for downstream imaging, proteomic and genomic analysis, with revenues driven by product sales, laboratory services and lab-developed tests through CRO, clinical lab and strategic partnerships.
Average Trading Volume: 2,086,842
Technical Sentiment Signal: Sell
Current Market Cap: £11.65M
For detailed information about CLBX stock, go to TipRanks’ Stock Analysis page.